SCHEMBL2615403

SCHEMBL2615403

Cn1ccc(-c2ccc(Cl)cc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.64
KMT2A Q03164 2/20 0.63
SCN4A P35499 1/20 0.53
CYP19A1 P11511 1/20 0.51
KCNH2 Q12809 1/20 0.47
GRIN2B Q13224 1/20 0.47
NPC1 O15118 9/20 0.44
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
PIK3CD O00329 1/20 0.42
PIP5K1C O60331 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PI4KA P42356 1/20 0.42
PIK3CG P48736 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
RAB9A P51151 8/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28088809 0.81 RAB9A (0.43) KEAP1KMT2ASCN4ANPC1RAB9A
SCHEMBL12319225 0.80 KEAP1 (0.67) KEAP1KMT2ASCN4ACYP19A1NPC1
SCHEMBL9258776 0.79 KEAP1 (0.66) KEAP1KMT2ASCN4ACYP19A1NPC1
SCHEMBL15885670 0.78 KEAP1 (0.64) KEAP1KMT2ASCN4ACYP19A1NPC1
SCHEMBL1160801 0.78 KEAP1 (1.00) KEAP1KMT2ASCN4ACYP19A1NPC1
SCHEMBL989300 0.78 SCN4A (0.79) KEAP1KMT2ASCN4ACYP19A1NPC1
SCHEMBL28424808 0.78 KEAP1 (0.64) KEAP1KMT2ASCN4ACYP19A1PIK3CD
SCHEMBL645457 0.78 KEAP1 (0.64) KEAP1KMT2ASCN4ACYP19A1KCNH2
SCHEMBL19356896 0.78 KEAP1 (0.64) KEAP1KMT2ASCN4ACYP19A1PIK3CD
SCHEMBL29598873 0.78 KEAP1 (0.53) KEAP1KMT2ASCN4ACYP19A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0389189-B1 Diazepine antiallergy agents PFIZER LTD (GB) 1994-05-18 EP claimed
US-5008263-A Platelet activating factor antagonists; antiallergens; antiinflammatory agents PFIZER INC. (US) 1991-04-16 US claimed
CN-1045783-A Diaza  class anti-allergy medicament PFIZER (US) 1990-10-03 CN claimed
EP-0389189-A2 Diazepine antiallergy agents Pfizer Limited (GB) 1990-09-26 EP claimed
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
CN-118745155-B Photoinitiated N-alkyl removal method 山东第一医科大学(山东省医学科学院) 2025-01-17 CN disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 CN disclosed
CN-118745155-A Photoinitiated N-alkyl removal method 山东第一医科大学(山东省医学科学院) 2024-10-08 CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
US-8785445-B2 7-phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC. (US) 2014-07-22 US disclosed
US-20120101103-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES ARRAY BIOPHARMA INC. (US) 2012-04-26 US disclosed
US-7279474-B2 Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) GLAXO GROUP LIMITED (GB) 2007-10-09 US disclosed
EP-0389189-B1 Diazepine antiallergy agents PFIZER LTD (GB) 1994-05-18 EP disclosed
US-5008263-A Platelet activating factor antagonists; antiallergens; antiinflammatory agents PFIZER INC. (US) 1991-04-16 US disclosed
CN-1045783-A Diaza  class anti-allergy medicament PFIZER (US) 1990-10-03 CN disclosed
EP-0389189-A2 Diazepine antiallergy agents Pfizer Limited (GB) 1990-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 KEAP1 1521/4885KMT2A 3129/4885SCN4A 4294/4885
US-20120101103-A1 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES PTGDR2, PTGDR, HRH2 KEAP1 2680/4885KMT2A 2184/4885SCN4A 3340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.